“Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial”, J of Skin, vol. 6, no. 6, p. s62, Nov. 2022, doi: 10.25251/skin.6.supp.62.